Responsive neurostimulation device

NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million

Retrieved on: 
Tuesday, March 5, 2024
Hemispherectomy, Project, Investment, FDA, Telephone, Growth, IDE, RNS, Conference, Responsive neurostimulation device, EEG, Webcast, Patient, United, Epilepsy, Idiopathic generalized epilepsy, Pivotal, CARE, Video game

MOUNTAIN VIEW, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Total revenue in the fourth quarter of 2023 grew 41% to $18.0 million, compared with $12.8 million in the fourth quarter of 2022, and increased 10% compared with $16.4 million in the third quarter of 2023.
  • R&D expense in the fourth quarter of 2023 was $5.4 million compared with $5.1 million in the same period of 2022.
  • SG&A expense in the fourth quarter of 2023 was $13.2 million compared with $13.6 million in the prior year period.
  • Loss from operations was $27.2 million in 2023, including $9.6 million of stock-based compensation, compared with $40.8 million in 2022.

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

Retrieved on: 
Monday, January 8, 2024
Patient, Responsive neurostimulation device, Conference, Biotechnology, Epilepsy, FDA, Data analysis, Idiopathic generalized epilepsy, Health, RNS, Clinical trial, ATM, Hemispherectomy, IGE, Machine learning, Growth, Investment, Project, Safety, Intelligence, Pharmaceutical industry

NeuroPace plans to release its fourth quarter and full year 2023 financial results in early March of 2024.

Key Points: 
  • NeuroPace plans to release its fourth quarter and full year 2023 financial results in early March of 2024.
  • Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for the fourth quarter ended December 31, 2023, representing growth of 37% to 41% versus the fourth quarter of 2022.
  • Total full year 2023 revenue expected to be between $64.9 million and $65.4 million grew 43% to 44% versus full year 2022 and came in well above initial 2023 revenue guidance of $50-$52 million.
  • To support these efforts, the Company plans to make some incremental additions to its sales and support teams.

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Retrieved on: 
Thursday, December 21, 2023
Consciousness, Patient, Responsive neurostimulation device, Injury, Food, Epilepsy, Depression, FDA, SUDEP, Idiopathic generalized epilepsy, Ageing, Trial of the century, Brain, RNS, IGE, IDE, Death, Social, Seizure, Nursing

MOUNTAIN VIEW, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial, growth-stage, medical technology company focused on transforming the lives of people living with epilepsy, today announced the completion of the patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule.

Key Points: 
  • “We are extremely proud to have completed patient enrollment in our NAUTILUS pivotal study significantly ahead of schedule,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We would like to recognize and thank the clinical investigators and patients that have enrolled in this important and groundbreaking trial.
  • Forty percent of drug-refractory epilepsy patients are diagnosed with generalized epilepsy, and NeuroPace believes that this early patient enrollment milestone is reflective of the excitement amongst patients and clinicians in potentially addressing this significant unmet need with the RNS System.
  • If the study achieves its primary endpoints, NeuroPace plans to submit a PMA Supplement and also intends to publish findings in a peer-reviewed medical journal.

NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

Retrieved on: 
Monday, December 4, 2023
Responsive neurostimulation device, Biotechnology, Agreement, Epilepsy, Becker, Data analysis, RNS, Clinical trial, Artificial intelligence, Biomarker, Machine learning, Patient, Nursing

MOUNTAIN VIEW, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a growth-stage medical technology company focused on transforming the lives of people living with epilepsy, today announced a first of its kind strategic collaboration that will leverage RNS System’s unique biomarker monitoring and data analysis capabilities. This collaboration will evaluate biomarker changes in currently implanted RNS System patients that have enrolled in a clinical-stage biotechnology company’s (“Company”) clinical trial of its product candidate.

Key Points: 
  • This collaboration will evaluate biomarker changes in currently implanted RNS System patients that have enrolled in a clinical-stage biotechnology company’s (“Company”) clinical trial of its product candidate.
  • “This groundbreaking collaboration demonstrates the value that our RNS System can provide through its proven ability to collect and analyze data, which is then used to generate insights that can help inform treatment strategies,” said Joel Becker, President and Chief Executive Officer of NeuroPace.
  • “Our team has analyzed retrospective data from thousands of patients demonstrating that biomarker changes captured by the RNS System may be predictive of clinical outcomes.
  • It is an initial step into extending the benefits of and generating value for patients and clinicians from our data monitoring and analysis capabilities with the potential to provide a basis for additional future collaborations.”

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Friday, December 1, 2023
Responsive neurostimulation device, Epilepsy, Generalization, LGS, AES, Hemispherectomy, IGE, Patient, RCT

“The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.

Key Points: 
  • “The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We look forward to collaborating with the many healthcare providers, scientists, and others from all over the world who are gathering in Orlando to promote better outcomes for people with epilepsy.
  • We will host various presentations and events highlighting our RNS System and look forward to engaging with the broader scientific community in the epilepsy field.”
    Over 50 original scientific presentations and posters regarding the RNS System will be presented throughout the meeting, as well as a number of general meeting sessions that include how the RNS System provides an important therapy option for the treatment of drug resistant epilepsy.
  • These presentations, posters, and events involve key opinion leaders as well as early career scientists and clinicians, all of whom aim to improve the lives of patients living with drug-resistant epilepsy.

NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

Retrieved on: 
Monday, November 6, 2023
FDA, Insurance, Sale, Neurosurgery, Physician, RNS, SG, Telephone, CEC, Conference, Project, TRM, Research, Growth, Marketing, Webcast, Partnership, Lender option borrower option, Epilepsy, EEG, Investment, Patient, Responsive neurostimulation device, Pharmaceutical industry, Rare-earth element, Video game, Nursing

MOUNTAIN VIEW, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Achieved total revenue of $16.4 million for the third quarter of 2023, representing a 47% increase over the third quarter of 2022.
  • Gross margin for the third quarter of 2023 was 74.5% compared to 71.4% in the third quarter of 2022 and 72.5% in the second quarter of 2023.
  • Total cash burn in the third quarter of 2023 was $2.2 million, a reduction from $4 million in the second quarter of 2023 and $9.8 million in the first quarter of 2023.
  • NeuroPace will host a conference call to discuss the third quarter 2023 financial results after market close on Monday, November 6, 2023, at 4:30 P.M. Eastern Time.

NeuroPace Announces RNS System Enhancements Designed to Streamline Care

Retrieved on: 
Tuesday, October 17, 2023
Physician, Quality of life, RNS, TRM, Food, Health, Epilepsy, Responsive neurostimulation device, US Foods, Workflow, Quality, Patient, Medical device, Nursing

MOUNTAIN VIEW, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced a series of key enhancements to its RNS System, all designed to streamline care. The nSight Platform, Simple Set Programming, and the Tablet Remote Monitor are all designed to simplify the experience with the RNS System for both clinicians and patients, and to improve patient care.

Key Points: 
  • The nSight Platform, Simple Set Programming, and the Tablet Remote Monitor are all designed to simplify the experience with the RNS System for both clinicians and patients, and to improve patient care.
  • The RNS System is the only commercially available closed-loop system for the treatment of drug-resistant focal epilepsy.
  • By continuously monitoring brain activity, the RNS System can detect abnormal activity and respond to that activity before it results in a clinical seizure.
  • The RNS System then records those events, allowing the clinician to use the data to actively manage patient care.

NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

Retrieved on: 
Tuesday, August 8, 2023
Epilepsy, Insurance, LGS, Partnership, SG, Telephone, Lennox–Gastaut syndrome, Clinical trial, Neurosurgery, Hemispherectomy, Level 4, Trial of the century, Responsive neurostimulation device, Patient, Physician, Investment, EEG, Webcast, Growth, FDA, Conference, NIH, RNS, Total, Pharmaceutical industry, Clothing, Rare-earth element, Video game, Nursing

MOUNTAIN VIEW, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Achieved total revenue of $16.5 million for the second quarter of 2023, representing a 62% increase over the second quarter of 2022.
  • Gross margin for the second quarter of 2023 was 72.5% compared to 73.2% in the second quarter of 2022 and 71.7% in the first quarter of 2023.
  • Net loss was $9.1 million for the second quarter of 2023, compared to a net loss of $12.7 million in the second quarter of 2022.
  • NeuroPace will host a conference call to discuss the second quarter 2023 financial results after market close on Tuesday, August 8, 2023, at 4:30 P.M. Eastern Time.

NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

Retrieved on: 
Thursday, May 4, 2023
Epilepsy, Lender option borrower option, Life, Sale, Trial of the century, Responsive neurostimulation device, Reflex seizure, Patient, Investment, EEG, Webcast, Growth, News, Total, Pharmaceutical industry, Video game, Nursing

MOUNTAIN VIEW, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Replacement implant revenue declined compared to the prior year period and represented less than 10% of total revenue in the first quarter of 2023.
  • Gross margin for the first quarter of 2023 was 72% compared to 73% in the first quarter of 2022 and 69% in the fourth quarter of 2022.
  • SG&A expense in the first quarter of 2023 was $13.4 million compared with $12.4 million in the prior year period.
  • NeuroPace will host a conference call to discuss the first quarter 2023 financial results after market close on Thursday, May 4, 2023, at 4:30 P.M. Eastern Time.

NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 2, 2023
Epilepsy, News, Responsive neurostimulation device, Patient, Reflex seizure, Sale, Electrode, Trial of the century, Webcast, Total, Growth, Partnership, EEG, Video game, Nursing, Pharmaceutical industry, Cryptocurrency

Achieved total revenue of $12.8 million for the fourth quarter of 2022, representing a 16% increase over the fourth quarter of 2021

Key Points: 
  • Achieved total revenue of $12.8 million for the fourth quarter of 2022, representing a 16% increase over the fourth quarter of 2021
    Achieved initial implant revenue of $9.8 million for the fourth quarter of 2022, representing a 15% increase over the fourth quarter of 2021
    Generated $1.6 million of revenue in the fourth quarter of 2022 from the distribution of DIXI Medical products, marking the first quarter of revenue contributions from the distribution arrangement
    “Our strong fourth quarter results were driven by increasing utilization of the RNS System and initial contributions from our exclusive U.S. distribution of stereo EEG electrodes produced by DIXI Medical.
  • Gross margin for the fourth quarter of 2022 was 69% compared to 73% in the fourth quarter of 2021.
  • Total operating expenses in the fourth quarter of 2022 were $18.7 million, compared with $17.1 million in the prior year period.
  • NeuroPace will host a conference call to discuss the fourth quarter and full year 2022 financial results after market close on Thursday, March 2, 2023, at 4:30 P.M. Eastern Time.